Dr. Elizabeth Murray is a certified practising speech pathologist in private practice and also a Lecturer at the University of Sydney, Australia. She completed her PhD in treatment efficacy for children with childhood apraxia of speech (CAS) with supervisors Associate Professor Tricia McCabe and Professor Kirrie Ballard. This included publishing studies investigating diagnosis of suspected CAS, a world-first randomised control trial comparing the Nuffield Dyspraxia Programme (3rd edition) to the Rapid Syllable Transition treatment and a systematic review of treatment options across all levels of evidence for children with CAS. Recently with Jacqueline McKechnie and Pamela Williams, she has investigated which children have responded well to the NDP3 to help determine who are good candidates for the treatment.
Elizabeth has worked clinically for over 10 years in Sydney with children with CAS and other speech sound disorders in disability, community health, non-for-profit and private practice settings. She has realised through her work that there is a gap between how the NDP3 is used in the UK versus Australia. She is passionate about improving treatment outcomes for children with CAS and other speech sound disorders in research and practice.